0001062993-23-020923.txt : 20231115
0001062993-23-020923.hdr.sgml : 20231115
20231115164203
ACCESSION NUMBER: 0001062993-23-020923
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231113
FILED AS OF DATE: 20231115
DATE AS OF CHANGE: 20231115
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jewell Christopher M
CENTRAL INDEX KEY: 0002000226
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37798
FILM NUMBER: 231411144
MAIL ADDRESS:
STREET 1: C/O CARTESIAN THERAPEUTICS, INC.
STREET 2: 704 QUINCE ORCHARD RD
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cartesian Therapeutics, Inc.
CENTRAL INDEX KEY: 0001453687
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 65 GROVE STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-923-1400
MAIL ADDRESS:
STREET 1: 65 GROVE STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: SELECTA BIOSCIENCES INC
DATE OF NAME CHANGE: 20090109
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2023-11-13
0001453687
Cartesian Therapeutics, Inc.
RNAC
0002000226
Jewell Christopher M
C/O CARTESIAN THERAPEUTICS, INC.
65 GROVE STREET
WATERTOWN
MA
02472
0
1
0
0
Chief Scientific Officer
0
Stock Option (Right to Buy)
107.59
2023-11-13
4
A
0
4276.454
A
2033-01-15
Series A Non-Voting Convertible Preferred Stock
4276.454
4276.454
D
Option is currently exercisable for 2,539.177 shares of Series A Non-Voting Convertible Preferred Stock of the issuer ("Series A Preferred Stock") and becomes exercisable for an additional 89.093 shares each month until it is fully exercisable.
Following the approval by the stockholders of the issuer of the conversion of the Series A Preferred Stock into shares of common stock of the issuer ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.
On November 13, 2023, the issuer acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Cartesian common stock held by the reporting person were converted into options to purchase shares of Series A Preferred Stock in connection with the acquisition.
/s/ Christopher M. Jewell
2023-11-15